Company Description
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.
It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells.
The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results.
The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.
| Country | Hong Kong |
| Founded | 2014 |
| IPO Date | Mar 6, 2025 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Xiaomin Chen |
Contact Details
Address: Tower 1, W MEGA, Units No. 12, 12th Floor Tsuen Wan Hong Kong | |
| Phone | 852 3158 0999 |
| Website | advb.ai |
Stock Details
| Ticker Symbol | ADVB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1941029 |
| CUSIP Number | 00752P203 |
| ISIN Number | US00752P2039 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Xiaomin Chen Ph.D. | Chief Executive Officer and Chairman |
| Mingze Yin | Chief Financial Officer and Director |
| - Alan | Director of Investor Relations |
| Dr. Hung To Pau Ph.D. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | 10-K | Annual Report |
| Sep 28, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Sep 22, 2026 | SCHEDULE 13G | Filing |
| Aug 20, 2026 | SCHEDULE 13G/A | Filing |
| Aug 20, 2026 | SCHEDULE 13G | Filing |
| Jul 20, 2026 | RW | Filing |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 4, 2026 | DEF 14A | Other definitive proxy statements |